Anemia Clinical Trial
Official title:
Testing Iron Absorption From a New Micronutrient Powder Containing Galacto-oligosaccharides (GOS) for Fortification of Infant Foods in Sub-Saharan Africa
Infants and young children in sub-Saharan Africa have high rates of iron deficiency anemia
(IDA), which adversely affects their growth and cognitive development. In-home iron
fortification of complementary foods using micronutrient powders (MNPs) reduces risk for IDA
by ensuring that the iron needs of infants and young children are met without changing their
traditional diet. In order to optimize iron absorption timing of MNP consumption might as
well be important. This is because hepcidin, a key regulator of systemic iron balance, shows
a circadian increase that may influence morning versus afternoon iron absorption from the
MNP. Furthermore, a single dose of iron can increase hepcidin levels and potentially inhibit
iron absorption from a second dose, consumed close in time to the first dose.
To determine the difference between i) morning versus afternoon iron absorption and ii)
consecutive versus alternate day iron absorption, investigators will enrol 20 infants from
Kwale County aged 6-14 months and conduct two studies. In study 1, infants will consume 2
test meals consisting of maize porridge containing isotopically labelled Ferrous Sulphate in
the morning and afternoon on 2 days. In study 2, infants will consume 3 test meals consisting
of maize porridge containing isotopically labelled Ferrous Sulphate on two consecutive days
and 1 alternate day. In both studies, fourteen days after the last test meal administration,
a whole blood sample will be collected by venipuncture for iron isotopic analysis. Iron and
inflammation status parameter will be determined at baseline and endpoint. Hepcidin
concentrations will be measured before the morning and afternoon meals (study 1) and after
second consecutive meal (study 2).
Knowing the effect of time on the expected iron absorption will inform decisions on the ideal
timing of MNP to cover the infant's requirement for absorbed iron.
20 infants will be recruited from the Msambweni County Referral Hospital in southern coastal
Kenya to participate in both studies.
Study 1:
At baseline a morning blood sample will be collected from potential study participants for
the determination of the following iron and inflammation status parameters: hemoglobin (Hb),
hepcidin, plasma ferritin (PF), soluble transferrin receptor (sTfR), zinc protoporphyrin
(ZnPP), C-reactive protein (CRP), alpha-1-acid glycoprotein (AGP). Anthropometrics (height,
weight, mid-upper arm and head circumference) will be measured, and demographics, the medical
history and the feeding habits will be assessed using a questionnaire.
Infants will consume the 1st test meal the next day after enrolment in the morning (day1). On
day 2 a 2nd blood sample (1ml) will be collected in the afternoon quantify afternoon
concentration of hepcidin in plasma and then the infants will consume the 2nd meal on the 3rd
day in the afternoon.
The two isotopically labelled test meals will be fed to the infants by their caregivers under
supervision of the research team. The morning test meal A will contain 12 mg of iron as
ferrous sulfate given as 2 mg of 57Fe and 10mg of 56Fe. The afternoon test meal will contain
12 mg of iron as ferrous sulfate given as 2 mg of 58Fe and 10 mg of 56Fe.
The test meals will consist of maize porridge (5-10% dry weight) and mineral water (8ml) and
will be randomly administered on the two alternate days (AB or BA). Overnight, only breast
milk will be allowed to the infant before coming for the morning meal and no breast milk will
be given at least 3 h before both morning and afternoon test meal administration. Infants
will not be allowed to eat or drink for 2 h after the test meal. Fourteen days after the
second test meal administration, 3 ml of whole blood will be collected by venipuncture for
iron isotopic analysis and iron and inflammation status. Anthropometrics and health status
will be assessed.
Study 2:
At baseline a blood sample will be collected from potential study participants for the
determination of iron and inflammation status parameters: hemoglobin (Hb), hepcidin, plasma
ferritin (PF), soluble transferrin receptor (sTfR), zinc protoporphyrin (ZnPP), C-reactive
protein (CRP), alpha-1-acid glycoprotein (AGP). Anthropometrics (height, weight, mid-upper
arm and head circumference) will be measured, and demographics, the medical history and the
feeding habits will be assessed using a questionnaire.
Infants will be randomized to consume the consecutive days or alternate day meal schedule on
day 1. 1ml of blood will be collected after the second consecutive meal to determine hepcidin
level.
Test meal A will contain 12 mg of iron as ferrous sulfate given as 2 mg of 54Fe and 10mg of
56Fe. Test meal B will contain 12 mg of iron as ferrous sulfate given as 2 mg of 57Fe and
10mg of 56Fe. Test meal C will contain 12 mg of iron as ferrous sulfate given as 2 mg of 58Fe
and 10mg of 56Fe. All test meals will be consumed in the morning.
The test meals will consist of maize porridge (5-10% dry weight) and mineral water (8ml).
Overnight, only breast milk will be allowed to the infant and no breast milk will be given at
least 3 h before test meal administration. Test meals plus mineral water will be consumed
completely in the presence of the investigators, and the infant will not be allowed to eat or
drink for 2 h after the test meal. Fourteen days after the third test meal, 3 ml of whole
blood will be collected by venipuncture for iron and inflammation status, and iron analysis
in red blood cells.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 |